Arbutus Biopharma (ABUS) Downgraded by Zacks Investment Research
Zacks Investment Research lowered shares of Arbutus Biopharma (NASDAQ:ABUS) from a buy rating to a hold rating in a report issued on Tuesday morning.
According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. “
A number of other brokerages have also issued reports on ABUS. Chardan Capital dropped their price target on shares of Arbutus Biopharma from $12.00 to $6.50 and set a buy rating on the stock in a research note on Friday, October 12th. BidaskClub lowered shares of Arbutus Biopharma from a strong-buy rating to a buy rating in a research report on Thursday, October 11th. B. Riley upgraded shares of Arbutus Biopharma from a neutral rating to a buy rating and lowered their price target for the company from $11.50 to $9.00 in a research report on Tuesday, October 16th. ValuEngine downgraded shares of Arbutus Biopharma from a strong-buy rating to a buy rating in a research note on Tuesday, October 9th. Finally, Wedbush increased their price target on shares of Arbutus Biopharma from $6.00 to $7.00 and gave the stock a hold rating in a research note on Monday, August 13th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $6.38.
Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.13). The business had revenue of $1.59 million during the quarter, compared to analyst estimates of $0.23 million. Arbutus Biopharma had a negative return on equity of 91.36% and a negative net margin of 1,116.69%. On average, analysts anticipate that Arbutus Biopharma will post -1.49 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in ABUS. Legal & General Group Plc increased its position in shares of Arbutus Biopharma by 367.7% in the third quarter. Legal & General Group Plc now owns 24,540 shares of the biopharmaceutical company’s stock worth $232,000 after acquiring an additional 19,293 shares in the last quarter. MetLife Investment Advisors LLC acquired a new stake in Arbutus Biopharma in the third quarter valued at approximately $270,000. Alliancebernstein L.P. acquired a new stake in Arbutus Biopharma in the third quarter valued at approximately $282,000. Rhumbline Advisers acquired a new stake in Arbutus Biopharma in the second quarter valued at approximately $243,000. Finally, Algert Global LLC acquired a new stake in shares of Arbutus Biopharma in the second quarter worth $254,000. Institutional investors own 42.59% of the company’s stock.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).
Featured Story: Do closed-end mutual funds pay dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.